COMP <GO>
XENE vs ACAD // RSI-14 & 200D SMA MOMENTUM
Xenon Pharmaceuticals Inc. (NASDAQ) VS. ACADIA Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: XENE 2
— ACAD 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ACAD
LAST: $37.54 (+3.30%) • MKT CAP: $3.64B
rsi-technicals
44.9
LAST: $20.76 (+2.17%) • MKT CAP: $3.58B
rsi-technicals
45.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. ACAD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | ACAD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 91.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 7.90% | -42.90 | ACAD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.70% | 2.94% | -10.64 | ACAD | /fcf-yield <GO> |
| Operating Margin | -36.70% | 9.80% | -46.50 | ACAD | /operating-margins <GO> |
| Net Profit Margin | -34.00% | 36.50% | -70.50 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 11.90% | -4.20 | ACAD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.26 | +19.74 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ACAD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 44.9 | 45.5 | -0.62 | ACAD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 8.5x | +20.50 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.64B | $3.58B | $58.3M | XENE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | ACAD REV | XENE GROSS % | ACAD GROSS % | XENE FCF | ACAD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.07B | — | 91.7% | -$279.9M | $105.1M |
| FY 2024 | $0 | $957.8M | — | 91.5% | -$184.5M | $157.2M |
| FY 2023 | $0 | $726.4M | — | — | -$151.1M | $16.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
ACAD // BETA —